Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of VitaNova Life Sciences Corp from 31 Oct 2018 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
VitaNova Life Sciences Corp quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Oct 2018 to 31 Oct 2025.
  • VitaNova Life Sciences Corp Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Oct 2025 was $99,290, a 63% increase year-over-year.
  • VitaNova Life Sciences Corp Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 31 Oct 2025 was $1,255,793, a 394% increase year-over-year.
  • VitaNova Life Sciences Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $1,204,304, a 485% increase from 2023.
  • VitaNova Life Sciences Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $205,734.
  • VitaNova Life Sciences Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $24,227, a 117% decline from 2021.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

VitaNova Life Sciences Corp Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,255,793 $99,290 +$38,515 +63% 01 Aug 2025 31 Oct 2025 10-Q 15 Dec 2025 2026 Q2
Q2 2025 $1,217,278 $32,440 +$12,974 +29% 01 May 2025 31 Jul 2025 10-Q 12 Sep 2025 2026 Q1
Q1 2025 $1,204,304 $1,080,686 +$847,898 +364% 01 Feb 2025 30 Apr 2025 10-K 24 Jul 2025 2025 FY
Q4 2024 $356,406 $108,257 +$102,309 +1720% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q3
Q3 2024 $254,097 $60,775 +$69,530 01 Aug 2024 31 Oct 2024 10-Q 15 Dec 2025 2026 Q2
Q2 2024 $184,567 $45,414 -$21,167 -87% 01 May 2024 31 Jul 2024 10-Q 12 Sep 2025 2026 Q1
Q1 2024 $205,734 $232,788 +$237,173 01 Feb 2024 30 Apr 2024 10-K 24 Jul 2025 2025 FY
Q4 2023 $31,439 $5,948 +$30,525 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q3
Q3 2023 $61,964 $8,755 -$11,356 -437% 01 Aug 2023 31 Oct 2023 10-Q 13 Dec 2024 2025 Q2
Q2 2023 $50,608 $24,247 -$26,381 -1236% 01 May 2023 31 Jul 2023 10-Q 10 Sep 2024 2025 Q1
Q1 2023 $24,227 $4,385 +$22,422 +84% 01 Feb 2023 30 Apr 2023 10-K 29 Jul 2024 2024 FY
Q4 2022 $46,649 $24,577 -$33,494 -376% 01 Nov 2022 31 Jan 2023 10-Q 11 Mar 2024 2024 Q3
Q3 2022 $13,155 $2,601 -$12,408 -83% 01 Aug 2022 31 Oct 2022 10-Q 15 Dec 2023 2024 Q2
Q2 2022 $747 $2,134 -$140,429 -99% 01 May 2022 31 Jul 2022 10-Q 14 Sep 2023 2024 Q1
Q1 2022 $139,682 $26,807 -$1,244 -4.9% 01 Feb 2022 30 Apr 2022 10-K 15 May 2023 2023 FY
Q4 2021 $140,926 $8,917 +$11,816 01 Nov 2021 31 Jan 2022 10-Q 17 Feb 2022 2022 Q3
Q3 2021 $129,110 $15,009 +$27,394 01 Aug 2021 31 Oct 2021 10-Q 10 Nov 2021 2021 Q2
Q2 2021 $101,716 $142,563 +$153,810 01 May 2021 31 Jul 2021 10-Q 20 Aug 2021 2022 Q1
Q1 2021 $52,094 $25,563 01 Feb 2021 30 Apr 2021 10-K 16 May 2022 2022 FY
Q4 2020 $2,899 +$3,695 +56% 01 Nov 2020 31 Jan 2021 10-Q 17 Feb 2022 2022 Q3
Q3 2020 $12,385 +$7,134 +37% 01 Aug 2020 31 Oct 2020 10-Q 10 Nov 2021 2021 Q2
Q2 2020 $11,247 01 May 2020 31 Jul 2020 10-Q 20 Aug 2021 2022 Q1
Q4 2019 $6,594 +$30,102 +82% 01 Nov 2019 31 Jan 2020 10-Q 20 Mar 2020 2020 Q3
Q3 2019 $19,519 -$11,459 -142% 01 Aug 2019 31 Oct 2019 10-Q 06 Dec 2019 2020 Q2
Q4 2018 $36,696 01 Nov 2018 31 Jan 2019 10-Q 20 Mar 2020 2020 Q3
Q3 2018 $8,060 01 Aug 2018 31 Oct 2018 10-Q 06 Dec 2019 2020 Q2

VitaNova Life Sciences Corp Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,204,304 +$998,570 +485% 01 May 2024 30 Apr 2025 10-K 24 Jul 2025 2025 FY
2023 $205,734 +$229,961 01 May 2023 30 Apr 2024 10-K 24 Jul 2025 2025 FY
2022 $24,227 -$163,909 -117% 01 May 2022 30 Apr 2023 10-K 29 Jul 2024 2024 FY
2021 $139,682 +$191,776 01 May 2021 30 Apr 2022 10-K 15 May 2023 2023 FY
2020 $52,094 +$20,240 +28% 01 May 2020 30 Apr 2021 10-K 16 May 2022 2022 FY
2019 $72,334 -$523 -0.73% 01 May 2019 30 Apr 2020 10-K 05 Aug 2020 2020 FY
2018 $71,811 01 May 2018 30 Apr 2019 10-K 05 Aug 2020 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.